Diurnal intraocular pressure and blood pressure with two dosing regimens of brimonidine in normal tension glaucoma

Catherine Jui Ling Liu, Ching Yu Cheng, Yu Chieh Ko, Wen-Ming Hsu

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background. To compare the effects of 2 dosing regimens of brimonidine tartrate 0.2% on diurnal intraocular pressure (IOP) and systemic hemodynamics in patients with normal-tension glaucoma (NTG). Methods. Twenty NTG patients were enrolled and randomized to receive either brimonidine twice daily (BID) for 4 weeks followed by brimonidine 3 times daily (TID) for another 4 weeks, or in reverse order. Diurnal variations of IOP and ocular perfusion pressure (OPP), as well as the 24-hour ambulatory blood pressure (BP) and pulse rate, were evaluated at baseline and after treatment. Baseline and post-treatment data were compared using a paired Student's t test, and treatment effects were compared between regimens using a crossover-designed analysis of variance. Results. Both regimens decreased the mean (p<0.001) and minimum (p<0.001) diurnal IOP, and only the TID regimen decreased the maximum IOP with a marginal significance (p = 0.049). The TID regimen decreased the maximum OPP (p = 0.009) while the BID regimen caused no changes in OPP. No significant difference in IOP or OPP was noted between regimens at each time point. Neither regimen caused changes in BP or pulse rate as assessed using the 24-hour ambulatory monitoring device. Conclusions. The TID regimen of brimonidine produces similar reductions in diurnal IOP for NTG patients as the BID regimen, and it alone decreases the maximum OPP. Neither of the 2 regimens causes exaggerated nocturnal reduction of BP.

Original languageEnglish
Pages (from-to)465-471
Number of pages7
JournalJournal of the Chinese Medical Association
Volume67
Issue number9
Publication statusPublished - Sep 1 2004
Externally publishedYes

Fingerprint

Low Tension Glaucoma
Intraocular Pressure
Blood Pressure
Perfusion
Pressure
Heart Rate
Ambulatory Monitoring
Brimonidine Tartrate
Analysis of Variance
Therapeutics
Hemodynamics
Students
Equipment and Supplies

Keywords

  • Alpha-adrenergic agonist
  • Blood pressure
  • Glaucoma
  • Intraocular pressure
  • Perfusion

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Diurnal intraocular pressure and blood pressure with two dosing regimens of brimonidine in normal tension glaucoma. / Liu, Catherine Jui Ling; Cheng, Ching Yu; Ko, Yu Chieh; Hsu, Wen-Ming.

In: Journal of the Chinese Medical Association, Vol. 67, No. 9, 01.09.2004, p. 465-471.

Research output: Contribution to journalArticle

@article{c87ada2afc294e8d81ed533001b3920b,
title = "Diurnal intraocular pressure and blood pressure with two dosing regimens of brimonidine in normal tension glaucoma",
abstract = "Background. To compare the effects of 2 dosing regimens of brimonidine tartrate 0.2{\%} on diurnal intraocular pressure (IOP) and systemic hemodynamics in patients with normal-tension glaucoma (NTG). Methods. Twenty NTG patients were enrolled and randomized to receive either brimonidine twice daily (BID) for 4 weeks followed by brimonidine 3 times daily (TID) for another 4 weeks, or in reverse order. Diurnal variations of IOP and ocular perfusion pressure (OPP), as well as the 24-hour ambulatory blood pressure (BP) and pulse rate, were evaluated at baseline and after treatment. Baseline and post-treatment data were compared using a paired Student's t test, and treatment effects were compared between regimens using a crossover-designed analysis of variance. Results. Both regimens decreased the mean (p<0.001) and minimum (p<0.001) diurnal IOP, and only the TID regimen decreased the maximum IOP with a marginal significance (p = 0.049). The TID regimen decreased the maximum OPP (p = 0.009) while the BID regimen caused no changes in OPP. No significant difference in IOP or OPP was noted between regimens at each time point. Neither regimen caused changes in BP or pulse rate as assessed using the 24-hour ambulatory monitoring device. Conclusions. The TID regimen of brimonidine produces similar reductions in diurnal IOP for NTG patients as the BID regimen, and it alone decreases the maximum OPP. Neither of the 2 regimens causes exaggerated nocturnal reduction of BP.",
keywords = "Alpha-adrenergic agonist, Blood pressure, Glaucoma, Intraocular pressure, Perfusion",
author = "Liu, {Catherine Jui Ling} and Cheng, {Ching Yu} and Ko, {Yu Chieh} and Wen-Ming Hsu",
year = "2004",
month = "9",
day = "1",
language = "English",
volume = "67",
pages = "465--471",
journal = "Journal of the Chinese Medical Association",
issn = "1726-4901",
publisher = "Elsevier Taiwan LLC",
number = "9",

}

TY - JOUR

T1 - Diurnal intraocular pressure and blood pressure with two dosing regimens of brimonidine in normal tension glaucoma

AU - Liu, Catherine Jui Ling

AU - Cheng, Ching Yu

AU - Ko, Yu Chieh

AU - Hsu, Wen-Ming

PY - 2004/9/1

Y1 - 2004/9/1

N2 - Background. To compare the effects of 2 dosing regimens of brimonidine tartrate 0.2% on diurnal intraocular pressure (IOP) and systemic hemodynamics in patients with normal-tension glaucoma (NTG). Methods. Twenty NTG patients were enrolled and randomized to receive either brimonidine twice daily (BID) for 4 weeks followed by brimonidine 3 times daily (TID) for another 4 weeks, or in reverse order. Diurnal variations of IOP and ocular perfusion pressure (OPP), as well as the 24-hour ambulatory blood pressure (BP) and pulse rate, were evaluated at baseline and after treatment. Baseline and post-treatment data were compared using a paired Student's t test, and treatment effects were compared between regimens using a crossover-designed analysis of variance. Results. Both regimens decreased the mean (p<0.001) and minimum (p<0.001) diurnal IOP, and only the TID regimen decreased the maximum IOP with a marginal significance (p = 0.049). The TID regimen decreased the maximum OPP (p = 0.009) while the BID regimen caused no changes in OPP. No significant difference in IOP or OPP was noted between regimens at each time point. Neither regimen caused changes in BP or pulse rate as assessed using the 24-hour ambulatory monitoring device. Conclusions. The TID regimen of brimonidine produces similar reductions in diurnal IOP for NTG patients as the BID regimen, and it alone decreases the maximum OPP. Neither of the 2 regimens causes exaggerated nocturnal reduction of BP.

AB - Background. To compare the effects of 2 dosing regimens of brimonidine tartrate 0.2% on diurnal intraocular pressure (IOP) and systemic hemodynamics in patients with normal-tension glaucoma (NTG). Methods. Twenty NTG patients were enrolled and randomized to receive either brimonidine twice daily (BID) for 4 weeks followed by brimonidine 3 times daily (TID) for another 4 weeks, or in reverse order. Diurnal variations of IOP and ocular perfusion pressure (OPP), as well as the 24-hour ambulatory blood pressure (BP) and pulse rate, were evaluated at baseline and after treatment. Baseline and post-treatment data were compared using a paired Student's t test, and treatment effects were compared between regimens using a crossover-designed analysis of variance. Results. Both regimens decreased the mean (p<0.001) and minimum (p<0.001) diurnal IOP, and only the TID regimen decreased the maximum IOP with a marginal significance (p = 0.049). The TID regimen decreased the maximum OPP (p = 0.009) while the BID regimen caused no changes in OPP. No significant difference in IOP or OPP was noted between regimens at each time point. Neither regimen caused changes in BP or pulse rate as assessed using the 24-hour ambulatory monitoring device. Conclusions. The TID regimen of brimonidine produces similar reductions in diurnal IOP for NTG patients as the BID regimen, and it alone decreases the maximum OPP. Neither of the 2 regimens causes exaggerated nocturnal reduction of BP.

KW - Alpha-adrenergic agonist

KW - Blood pressure

KW - Glaucoma

KW - Intraocular pressure

KW - Perfusion

UR - http://www.scopus.com/inward/record.url?scp=9244249135&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9244249135&partnerID=8YFLogxK

M3 - Article

VL - 67

SP - 465

EP - 471

JO - Journal of the Chinese Medical Association

JF - Journal of the Chinese Medical Association

SN - 1726-4901

IS - 9

ER -